For UK pharmaceutical and life sciences leaders
Your Medical Affairs insights are not reaching the teams that need them most
When Medical Affairs and Commercial operate in silos, scientific intelligence fails to shape market strategy. Product launches slow, opportunities are missed, and duplicated systems quietly consume a significant share of your IT budget.
Two minutes. Solva follows up with specific cross-functional integration options.
- Medical Science Liaisons (MSLs) sharing scientific insights that are not integrated into commercial messaging
- Commercial teams developing promotional materials without sufficient medical input or scientific accuracy
- Product launch delays due to misaligned strategies between medical, market access, and commercial teams
- Duplication of data collection and analysis efforts by different departments
- Inefficient resource allocation and duplicated efforts across departments
- Slower decision-making processes due to lack of shared understanding and conflicting priorities
- Billions in lost revenue potential from delayed product launches and suboptimal market penetration
- Wasted investment in redundant technology and data platforms (up to 30% of IT budgets)
- Delayed patient access to innovative therapies due to market access hurdles
- Suboptimal patient outcomes from inconsistent or unclear medical information
- Erosion of trust with healthcare professionals and key opinion leaders
- Negative perception of the company's scientific credibility and patient-centricity
- Structural root causes include historical regulatory separation between medical and commercial activities, leading to distinct departmental objectives and KPIs.
- Behavioural factors involve a "silo mentality" where teams prioritize their own functional goals over shared organizational success.
- Systemic issues arise from disparate data platforms and a lack of unified leadership oversight that can effectively bridge the divide between scientific rigor and commercial imperatives.
Poor coordination between commercial and medical teams affects 40% of new drug launches (Pharmaphorum, 2025)
How to fix it
Establish cross-functional governance structures and shared KPIs to foster collaboration between Medical Affairs and Commercial teams. Implement integrated data platforms to ensure consistent messaging and a seamless flow of scientific and commercial insights.
Frequently asked questions
Why does this problem persist?
A lack of integrated strategy and communication channels between Medical Affairs and Commercial teams prevents a unified approach to market engagement. This misalignment can delay product launches, reduce market access, and dilute the impact of scientific data.
What is the cost of leaving it unaddressed?
Duplicated technology investments due to cross-functional silos can consume up to 30% of IT budgets in pharmaceutical companies (Pharmaphorum, 2025)
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.